(VIANEWS) – The NASDAQ ended the session with Viking Therapeutics rising 10.97% to $23.72 on Monday, following the last session’s downward trend. NASDAQ jumped 1.12% to $15,628.04, following the last session’s downward trend on what was an all-around bullish trend trading session today.
Viking Therapeutics’s last close was $21.37, 16.91% under its 52-week high of $25.72.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.92.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.12%.
Moving Average
Viking Therapeutics’s worth is way higher than its 50-day moving average of $17.49 and way above its 200-day moving average of $16.48.
More news about Viking Therapeutics (VKTX).
